- Candel Therapeutics is preparing for Biologics License Application (BLA) submission for **CAN-2409** in newly diagnosed localized prostate cancer, targeting **Q4 2026**, following positive pivotal Phase 3 data.  **[1841387_tx_380781_0]** **[1841387_tx_380781_4]** 
- The company reported over **$100 million** in cash at the end of Q2 2025, providing funding for operations into **Q1 2027**, which covers the BLA submission for the prostate cancer program.  **[1841387_tx_380781_9]** 
- Candel is also advancing **CAN-2409** in non-small cell lung cancer (NSCLC) and pancreatic cancer, with a pivotal Phase 3 trial for NSCLC planned to begin in **Q2 2026** pending non-dilutive funding.  **[1841387_tx_380781_0]** **[1841387_tx_380781_6]** **[1841387_tx_380781_7]** 
- The **CAN-3110** program for recurrent glioblastoma has shown encouraging data, including a doubling of expected median overall survival after a single injection, and a potentially registrational Phase 2 trial is being prepared.  **[1841387_tx_380781_0]** **[1841387_tx_380781_9]**

Candel Therapeutics (CADL)